Figure 2. BET inhibitors in clinical development (ABBV-075, I-BET762, CPI-0610) are variably effective in limiting CTCL cell viability.

(A) Representative dose-response curves of CTCL cells derived from patient 11 to different BET inhibitors. (B) Comparison of average IC₅₀s of BET inhibitors from patient-derived samples. ABBV-075 and JQ1 were tested against eight patient-derived samples; I-BET-762 and CPI-0610 were tested against five patient-derived samples. Patient codes and individual IC₅₀s are provided in Supplementary Table 1. ^*p < 0.05; ^**p < 0.01.